Tim Lugo
Stock Analyst at William Blair
(0.58)
# 3,739
Out of 4,789 analysts
28
Total ratings
35.29%
Success rate
-20.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $67.94 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.46 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $26.01 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $3.45 | +1,061.10% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $7.32 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $206.27 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $0.22 | - | 3 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.48 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $17.44 | - | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.53 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.34 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $7.86 | +688.80% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.85 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $30.64 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.10 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.31 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $22.60 | +103.54% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $67.94
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.46
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $26.01
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $3.45
Upside: +1,061.10%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.32
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $206.27
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.22
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.48
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.44
Upside: -
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.53
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.34
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $7.86
Upside: +688.80%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.85
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $30.64
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.10
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.31
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $22.60
Upside: +103.54%